



Figure S9


A




B




C



D



E



F




Figure S9. A. Flow plots showing gating strategies and markers used to define immune subtypes including M1 and M2 macrophages. B. Flow plots showing M1 and M2 macrophages in one out of five SKOV3 xenograft tumor tissues treated with Herceptin and ZL-1201 + Herceptin. C. Flow plots showing M1 and M2 macrophages in one out of five SKOV3 xenograft tumor tissues treated with paclitaxel (PTX) and ZL-1201 + PTX. D. Flow histogram showing SIRPa levels in SKOV3 xenograft tumor tissues treated with either isotype or ZL-1201. E. SIRPa levels on tumor-infiltrating macrophages analyzed by FACs analysis in HCC1954, SKOV3, and FaDu xenograft tumor tissues (n = 5) treated with either isotype or ZL-1201. E. SIRPa levels in M1 and M2 macrophages from SKOV3 xenograft tumor tissues (n = 5) relative to total macrophages. For E and F, data was shown as mean \pm SEM.